Calcium, natural vitamin D3, magnesium are present as precipitated calcium carbonate/cholecalciferol (vitamin D3)/magnesium carbonate combination in the tablets.
The medication is indicated for the treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab).
Two tablets are to be administered orally every day under normal circumstances and the dose can be increased or decreased depending on a patient’s condition and clinical test results.
Activities related to manufacturing and marketing of Denotas will be carried out by Nitto Pharmaceutical Industries.